Financial Shenanigans

Figures converted from KRW at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Financial Shenanigans

Forensic Risk Score: 72 / 100 — High. Five years of reported net income sum to roughly zero in dollar terms (under $1M), yet free cash flow over the same window is −$33.2M and operating cash flow has been propped up by financing of +$32.0M. FY2024 carries the single most concerning artifact in this filing set — cost of revenue collapsing from $22.4M to $3.1M while revenue grew 9.8%, lifting gross margin to 83%, alongside $24.7M of capex that briefly tripled fixed assets before $21.3M of that fixed-asset base dropped off the balance sheet again in FY2025. The board already approved a restatement of FY2023 consolidated financials in early 2025, and the company is controlled by a loss-making holding entity (Nextern Roll Korea) inside a multi-layer chain rising to ROA and Co. The single fact that would most change the grade is independent confirmation of where the FY2024 fixed assets went in FY2025 — a sale-leaseback, impairment recycle, or reclassification footnote would either resolve the cost-shift signal or harden it.

Shenanigans scorecard

The 13-category coverage map below uses the standard taxonomy. Six tests fail with material evidence, five flash yellow, and only two come back clean.

Breeding Ground

The control structure and the audit oversight are the weakest links in the file. This is a small-cap KOSDAQ semiconductor equipment maker with a 113-employee headcount, controlled through three layers of holding companies up to ROA and Co — a film/media-adjacent group with no operating connection to semiconductor equipment. The CEO Lee Chang-jae and the rest of the executive bench were installed on the same day Nextern Bioscience took control (2023-07-13). One outside director resigned mid-year FY2025 with 60% attendance. There is no audit committee — Korean small-cap law lets a standing auditor (Moon Hyung-suk, Hyundai Accounting Firm) stand in. Compensation is modest (no single director crossed the roughly $345K individual-disclosure threshold), so monetary incentive to manipulate is low, but stock options were granted with an exercise price of $8.96 to the CEO and President at the bottom of the cycle (2025-03-26), now well in the money at $18.22.

The breeding-ground map is decisively red. A new controller, weak independent oversight, a small-firm statutory auditor and a confirmed prior-period restatement together amplify the accounting flags below. The single soft spot in management's favor is that none of the named executives clears the disclosure threshold for individual compensation — direct cash-incentive pressure to bend numbers is modest. The mechanism worth worrying about is equity-linked: convertible bond #8 and #9 converted into 23.2M shares (pre-split) for Nextern between November 2024 and May 2025, immediately followed by the 16:1 reverse capital reduction on 2025-07-01. Stock options for the CEO and President were granted between those two events at $8.96 (post-split).

Earnings Quality

FY2024 reported earnings are not a faithful representation of underlying operations and FY2023 reported earnings were already restated. The cleanest forensic signal in this file is the FY2024 cost-of-revenue collapse alongside a one-time fixed-asset surge. COGS dropped 84% YoY while revenue grew. Gross margin jumped from −33.9% to 83.3%. In the same year capex was 36.6x depreciation and fixed assets nearly tripled. In FY2025 fixed assets unwound by $21.3M while non-current assets only grew $2.28M — meaning roughly $19M of the FY2024 fixed-asset build was reclassified into other non-current accounts or disposed without a matching cash receipt. The economic substance behind that flow has not been disclosed in the management discussion excerpt available.

The FY2024 COGS print is structurally implausible for a semiconductor test-handler maker that shipped 23 ATE units that year. Per-unit ATE revenue in FY2024 was around $353K (=$8.11M / 23). At a 60% gross margin assumption — which is the long-run norm for premium test handler peers — implied per-unit COGS would be roughly $141K, or $3.24M across 23 units. So the reported COGS figure of $3.07M is internally consistent with a 60% gross margin only if every shipped ATE handler had zero cost of materials and labor outside the equipment itself — implausible. The likelier explanation is that material, labor, and overhead were either capitalized into the roughly $21M of fixed-asset expansion, or held as inventory (FY2024 inventory turnover dropped to 0.36, implying DIO of roughly 1,014 days). FY2025's inventory turnover normalising to 1.13 and gross margin returning to 41.8% supports the cost-shift interpretation.

The capex-to-depreciation ratio averaged 0.5x in FY22–FY23 and then hit 36.6x in FY2024 and 16.1x in FY2025 — orders of magnitude above what an equipment maker with 97.5% factory utilisation should need to spend to support its growth trajectory. Fixed assets peaked at $32.51M at FY24 year-end and then dropped to $11.73M one year later, but non-current assets only grew $2.28M and there is no separately disclosed gain/loss-on-sale matching the magnitude. The line moved off fixed assets and into another non-current bucket, which is the textbook shape of either a sale-leaseback that flips fixed assets into a right-of-use asset or operating-lease receivable, or a reclassification into "investment property" / "intangibles" / "long-term financial assets". Either is permissible under K-IFRS but materially changes whether the earlier capex represented core-business investment.

Q4 FY2023 is the single most distorted quarter in the file. Revenue fell to $2.01M while operating loss landed at −$15.32M — implying the company recognised roughly $13M of one-shot costs against $2M of revenue (gross margin −586%). The big-bath quarter coincides with the first full quarter after the change of control. Q3 FY2024 then prints a 161% gross margin and operating income of $5.63M on revenue of $4.74M — economically impossible without one-time gains classified inside operating costs or inventory reversals. These two quarters bookend the FY2024 cost-shift pattern: bad-news pulled forward into late FY23, good-news pulled forward into FY24 once Nextern's controlling stake was fully fixed.

Cash Flow Quality

Operating cash flow does not support the reported income line. Cumulative net income over FY2021–FY2025 is roughly zero in dollar terms (under $1M); cumulative free cash flow is −$33.2M. The gap was closed by financing — $32.0M in net financing inflows from convertible bonds (CB #8 and #9, both converted), rights offerings, and bank borrowings ($9.65M drawn at FY25 against a $9.73M credit line). FY2025 operating cash flow swung to negative $3.57M even as reported net income reached $6.98M — a 5-year-low cash conversion print despite a 5-year-high earnings print.

The FY2022 figure is the cleanest illustration of the cash-flow problem in the file: net income $6.34M, operating cash flow $0.02M. The company reported strong profit while collecting essentially nothing from operations. FY2024 repeated the pattern (NI $4.49M, CFO $0.22M). FY2025 broke even further — net income $6.98M, CFO negative $3.57M — meaning the year that looks most prosperous on the income statement is the year operating cash actually went into reverse.

The FY2024 financing draw of $12.36M was the largest single-year cash injection in five years. The bulk of it funded the $24.66M capex line that produced the unexplained fixed-asset spike. By FY2025 the company drew $6.47M in financing while CFO went negative and $11.67M more capex landed — meaning even the latest year of strong reported revenue did not produce enough cash to fund the business. Without the bond conversions and bank lines, the cash balance would have fallen from $32.06M at FY21 to below zero rather than the $7.50M reported.

The shape is decisive. Over a 5-year period the business raised $32.0M from financing and burned through almost all of it — cash declined $24.56M (from $32.06M to $7.50M). On a steady-state basis, the company has consumed approximately $48M of cash from operations and investing combined. Whatever the reported earnings show, the cash engine is upside-down.

Metric Hygiene

Per-share figures are dominated by capital actions, not operations. Because Mirae files under K-IFRS as a small/mid-cap, no non-GAAP / adjusted-EBITDA reconciliation is published — eliminating one type of metric-distortion risk. The replacement risk is the capital-structure churn. From the start of FY2022 to the end of FY2025, shares outstanding moved 4.45M → 30.43M → 58.23M, then collapsed to 4.48M after a 16:1 reverse capital reduction on 2025-07-01. EPS comparisons therefore look orderly only because the reverse reduction backed-out earlier dilution.

The most surprising hygiene point is the customer concentration disclosure inside the FY2025 business report: a single Chinese counterparty named YILINING PRECISION delivered $19.80M (56.5%) of reported revenue, with two additional China-linked counterparties (CXMT, YMTC) adding meaningful volume. CXMT is on the US Entity List as of December 2024 and YMTC has been since December 2022. The customer book that drove FY2025's reported growth from $18.39M → $35.04M is highly concentrated, sanctioned-entity adjacent, and difficult to verify externally — exactly the profile where audit and revenue-recognition scrutiny should be at its sharpest.

What to Underwrite Next

Treat the accounting risk as thesis-relevant, not a footnote. Forensic risk of 72/100 is not an automatic short call — but it is enough to require a materially wider margin of safety than the headline $35M revenue and $7M net income suggest. Five practical diligence items to track before sizing this position:

1. Footnote the FY24 fixed-asset unwind. Identify in the FY2025 audited footnotes exactly what happened to the roughly $21M of fixed assets that vanished. Three candidate buckets: sale-leaseback (right-of-use reclassification), reclassification into investment property/intangibles/other non-current assets, or impairment with offsetting capitalised value reversed. Any answer other than a normal disposal with cash receipt validates the cost-shift signal.
2. Reconcile the FY24 cost-of-revenue print. Reconstruct unit-level COGS for the 23 ATE units delivered in FY2024. If reconstructed COGS materially exceeds the $3.07M reported figure, the gap was either capitalised into inventory or fixed assets.
3. Trace Yilining Precision. Confirm whether Yilining Precision / Yiling Trading is the same entity, identify its ultimate ownership and operating profile, and check for any sanctions or export-control exposure. A single Chinese counterparty supplying 56.5% of revenue is a thesis-grade risk in its own right.
4. Watch FY26 working capital signals. If Q1 FY2026 (already published — revenue $13.69M, net income $3.90M) is followed by another negative CFO print at H1, the cash-flow problem is structural, not a working-capital timing artifact.
5. Monitor any further restatement or "(정정)" disclosures. FY2023 was already restated; the disclosure index shows multiple amendments to single-customer supply contracts in 2025. A second prior-period restatement or an audit-firm change would push this file from High to Critical.

Bottom line. Mirae's reported FY2024 and FY2025 income statement is not a clean read of operating economics. The cash flow tells the truer story — the company has consumed cash for five straight years and relied on convertible bonds and bank lines to keep the cash balance above zero. The FY2023 restatement, the FY2024 cost-shift, the unexplained fixed-asset reversal in FY2025, the holding-company control chain and the 56.5% single-customer concentration are converging signals. This is a position-sizing limiter and a valuation haircut — not a footnote, and not yet a thesis-breaker. The upgrade path is full clean footnote disclosure on the fixed-asset unwind plus two consecutive quarters of positive operating cash flow. The downgrade path is a second restatement, an auditor change, or any export-control action affecting the Chinese customer book.